At Maypharm Lifesciences, our mission is “Driven To Bring More Smiles”. We are delighted to announce that our Managing Director, Sameer Kolhe, MD, was recently interviewed by the esteemed Pharma Click Daily Magazine on our strategic approach to global expansion.

In this exclusive feature, Sameer Kolhe lays out the blueprint that is powering our high-growth trajectory. We invite you to read the full interview and support our partners at the Pharma Click Daily Magazine.

Here are the key takeaways from the conversation that define Maypharm’s journey:

The Foundation: Value Creation

Our journey, which began in 2017, is driven by a single, unwavering vision: Value Creation. This philosophy means our core focus is “purely on how we create value” for all stakeholders, from patients to partners. By focusing on this principle, Maypharm ensures that every product and market strategy enhances the consumer experience.

Strategy Decoded: The 3M Framework

To successfully navigate complex international territories, Maypharm employs a distinct strategy known as the 3M Framework. This framework guides how we select and enter global markets:

• Molecule: Intelligent portfolio selection, focusing on products that offer unique value.

• Market: Defining strategic segments, geographies, and territories, with a focus on high-entry-barrier regions.

• Model: Tailoring the business model for optimal market penetration and sustainable success.

The LATAM & Consumer Health Pivot

Maypharm is currently in its commercial phase (post-2021) with a sharp focus on two critical growth areas:

• LATAM Focus: We are building direct subsidiaries in Brazil & Mexico, which together account for approximately 70% of the Latin American pharmaceutical market. This strong presence in high-entry-barrier regions is a cornerstone of our strategy.

• Consumer Health: We are diversifying into consumer wellness to boost brand visibility and enhance portfolio stability with value-added products.

The Future is Agile & Specialized

Maypharm demonstrates how an agile, new-age pharma company can succeed by specializing its approach, particularly in complex territories like LATAM. We follow a Spiral Growth Model, aiming to accelerate growth every 3-4 years by mastering product registration and market adaptation.